June 13, 2025

Breast Cancer Radiotherapy Leads to Moderate Cardiac Function Decline Over Years

Patients with breast cancer receiving radiation therapy demonstrated moderate changes in their cardiac function over a period of several years, and patients who received a maximum left anterior descen...

The ASCO Post

June 13, 2025

Prophylactic Radiation Therapy of the Contralateral Breast in BRCA Carriers with Early-Stage Breast Cancer

In a long-term follow-up of an Israeli phase II trial reported in a research letter in JAMA Oncology, Evron et al compared prophylactic radiation therapy of the contralateral breast vs surveillance in...

The ASCO Post

June 10, 2025

Study Shows Potential Benefits of AI-Assisted Classification in HER2-Low and HER2-Ultralow Breast Cancer

With the approval of HER2-targeted antibody-drug conjugate options for treating patients with breast cancer across different HER2 expression levels, accurate assessment of HER2 expression has become m...

The ASCO Post

June 10, 2025

Why Black Women Have a Higher Risk of Dying of All Types of Breast Cancer Than White Women

The disparities in breast cancer incidence and mortality rates between Black and White women in the United States have been well documented. Studies over the past decade consistently show that althoug...

The ASCO Post

June 10, 2025

Revisiting Margin Width Guidelines for Ductal Carcinoma In Situ and the Role of Routine Reexcision

For postmenopausal women with HR-positive ductal carcinoma in situ (DCIS) treated with breast-conserving surgery, whole-breast irradiation, and adjuvant endocrine therapy, reexcision to achieve wider ...

The ASCO Post

June 10, 2025

Conundrums in Treating HER2-Positive Early Breast Cancer

Today’s oncologists are blessed with an abundance of therapies for HER2-positive early breast cancer, but this comes with the challenge of selecting among them. At the 2025 Miami Breast Cancer Confere...

The ASCO Post

June 05, 2025

Preoperative THP Leads to pCR in Two-Thirds of Patients With Early-Stage HER2-Positive ER-Negative Breast Cancer

Patients with stage II and III (early-stage) HER2+ breast cancer usually undergo preoperative therapy with multiagent chemotherapy in combination with anti-HER2 antibodies, followed by surgery. A less...

The ASCO Post

June 01, 2025

ASCO 2025: Switching to Camizestrant After Detection of an ESR1 Mutation Improves Progression-Free Survival for Some Patients With Advanced Breast Cancer

The phase III SERENA-6 clinical trial evaluated whether switching to treatment with camizestrant if an ESR1 mutation is detected during first-line treatment can help to slow cancer growth for patients...

The ASCO Post

May 21, 2025

Association Between Risk-Reducing Surgeries and Survival in Young BRCA Carriers With Breast Cancer

In an international cohort study reported in The Lancet Oncology, Blondeaux et al evaluated whether both risk-reducing mastectomy and risk-reducing salpingo-oophorectomy were associated with improved ...

The ASCO Post